Q1 2026 · 13F-HR
Patient Square Capital LPholdings as filed
Filed 2026-05-15 · accession 0001819257-26-000003
$563.6M
Reported value
29
Positions
2026-03-31
Period end
The Brief · Patient Square Capital LP · Q1 2026
AI · grounded in 13F
Patient Square Capital LP established a new position in ROIV valued at $226.2M. The fund also initiated new stakes in ARGX for $26.8M and INSM for $25.8M. Additional new positions include ONC at $23.9M and COGT at $22.9M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $226.2M | 40.1% | 8,166,047 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $26.8M | 4.76% | 36,718 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $25.8M | 4.57% | 157,500 | Common | SOLE |
| 07725L102 | ONC | BEONE MEDICINES LTD | $23.9M | 4.24% | 80,542 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $22.9M | 4.07% | 596,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $21.2M | 3.77% | 230,000 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC | $18.6M | 3.30% | 116,684 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $17.9M | 3.18% | 990,000 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $15.1M | 2.68% | 210,000 | Common | SOLE |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A | $14.5M | 2.57% | 693,534 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $13.9M | 2.47% | 493,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $13.5M | 2.40% | 121,245 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $13.2M | 2.34% | 227,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $10.8M | 1.92% | 95,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT INC | $10.2M | 1.82% | 795,000 | Common | SOLE |
| 58933Y105 | MRK | MERCK & CO INC | $9.6M | 1.71% | 80,000 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $9.4M | 1.67% | 400,645 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $8.4M | 1.49% | 3,450,000 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $8.3M | 1.48% | 100,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $7.9M | 1.40% | 93,882 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $7.8M | 1.39% | 200,000 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $6.8M | 1.20% | 1,625,000 | Common | SOLE |
| 24477V105 | DFTX | DEFINIUM THERAPEUTICS INC | $6.3M | 1.11% | 331,000 | Common | SOLE |
| 415858109 | HROW | HARROW INC | $5.8M | 1.03% | 165,209 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $5.4M | 0.95% | 1,030,846 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC. | $5.1M | 0.91% | 1,085,790 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $4.2M | 0.75% | 195,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $3.8M | 0.67% | 136,315 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $50,440 | 0.01% | 1,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.